FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 188 filers reported holding FATE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 4.84 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,788 | -64.3% | 5,089 | -19.8% | 0.00% | – |
| Q2 2023 | $30,257 | -18.9% | 6,345 | -3.3% | 0.00% | – |
| Q1 2023 | $37,320 | -40.9% | 6,564 | +3.0% | 0.00% | – |
| Q4 2022 | $63,153 | +187.1% | 6,371 | +520.4% | 0.00% | – |
| Q3 2022 | $22,000 | +10.0% | 1,027 | +26.6% | 0.00% | – |
| Q2 2022 | $20,000 | -95.0% | 811 | -20.1% | 0.00% | -100.0% |
| Q1 2022 | $401,000 | +557.4% | 1,015 | +0.3% | 0.00% | – |
| Q4 2021 | $61,000 | -35.1% | 1,012 | -35.8% | 0.00% | – |
| Q3 2021 | $94,000 | -70.6% | 1,577 | -57.0% | 0.00% | -100.0% |
| Q2 2021 | $320,000 | +267.8% | 3,669 | +249.4% | 0.00% | – |
| Q1 2021 | $87,000 | -44.9% | 1,050 | -39.2% | 0.00% | – |
| Q4 2020 | $158,000 | -19.8% | 1,726 | -68.1% | 0.00% | -100.0% |
| Q3 2020 | $197,000 | +16.6% | 5,418 | +9.8% | 0.00% | 0.0% |
| Q2 2020 | $169,000 | +44.4% | 4,934 | +1.5% | 0.00% | – |
| Q1 2020 | $117,000 | – | 4,863 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |